Drug
SHP640
SHP640 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
300%(3 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
NCT02998541
completedphase_3
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
NCT03004924
terminatedphase_3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
NCT02998554
Clinical Trials (3)
Showing 3 of 3 trials
NCT02998541Phase 3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
NCT03004924Phase 3
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
NCT02998554Phase 3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3